Clinuvel Pharmaceuticals (ASX:CUV) broadens DNA repair programme
Clinuvel Pharmaceuticals (CUV) is expanding its clinical programme to test Scensse’s ability…
Clinuvel Pharmaceuticals Limited (CUV:ASX)
$41.71
0.61 (1.48%)
MCAP $2.030B
Last trade
16.10pm 17/09/2021
20mins delayed
Latest Announcements
16/09/2021CUVClinuvel Pharmaceuticals Limited
14/09/2021CUVClinuvel Pharmaceuticals Limited
27/08/2021CUVClinuvel Pharmaceuticals Limited
4,045
MCap
26/08/2021CUVClinuvel Pharmaceuticals Limited
412
MCap
26/08/2021CUVClinuvel Pharmaceuticals Limited
538
MCap
26/08/2021CUVClinuvel Pharmaceuticals Limited
26/08/2021 Price SensitivePSCUVClinuvel Pharmaceuticals Limited
4,247
MCap
26/08/2021 Price SensitivePSCUVClinuvel Pharmaceuticals Limited
Company Overview
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). It is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
